Global Ganja Report

Growing numbers around the United States and the world are using cannabis to treat a wide spectrum of medical conditions, and legal space is widening for them to do so. So it's a particular irony that hospitals as a rule bar cannabis from their premises. More voices in the medical industry are now grappling with this dilemma.

A ground-breaking study is set to begin in Australia, to determine if cannabis can improve the quality of life of those suffering from dementia. Elderly care facilities are watching closely, hoping cannabis will prove a key to help those they look after lead happier lives, with less medication.

Researchers are exploring the connection between cannabinoids and dopamine in the human brain, and particularly how THC affects our "reward system"—key to such phenomena as motivation, addiction and euphoria. Investigations are revealing both potential for treatments of psychiatric disorders as well as possible risks from heavy use, especially among the young.

Health authorities have named Vitamin E acetate as a likely suspect in the serious illness that has now affected hundreds across the country after vaping either cannabis or tobacco products. In many of the cases illicit-market dab carts appear to be responsible for the severe pulmonary problems that have now resulted in five deaths. But public authorities and the cannabis industry alike caution that research is ongoing.

Among the multiple grim challenges facing humanity at this moment is the specter of "antibiotic apocalypse"—so-called "superbugs" developing resistance to common antibiotics, portending a plague of incurable infections. Research in Australia now reveals anti-bacterial properties in CBD, effective even against the growing ranks of resistant superbugs. Many in the stateside cannabis industry say the development is further evidence that legal barriers to research need to come down—and fast.

The US Surgeon General has launched a new campaign hyping the supposed dangers of cannabis—a further disappointment for activists who held out hope that Trump harbored libertarian instincts and would legalize. All too predictably, the anti-legalization assumptions behind the new campaign are amply refuted by actual research.

The US Department of Agriculture is opening an Industrial Hemp Germplasm Repository, in conjunction with upstate New York's Cornell University. The facility is envisioned as a major hub for genetic analysis and research, helping to spur the hemp industry's growth regionally and nationally.

With industry waiting on the FDA to issue regs for CBD products, the agency instead released a statement explaining why it has not yet done so—including fears that the trendy cannabinoid may cause liver damage. But advocates charge that the claim is based on faulty research.